Selank (10MG)

Selank is a synthetic heptapeptide analogue of the endogenous immunomodulatory tetrapeptide tuftsin (Thr-Lys-Pro-Arg), with a C-terminal Pro-Gly-Pro extension that enhances metabolic stability. It was developed in Russia and is supplied as a lyophilized powder for in vitro research applications involving neuropeptide pharmacology, GABAergic signalling, and anxiety-related neurobiological pathway research.

Molecular Profile
CAS Number: 129954-34-3
Molecular Weight: 751.85 Da
Sequence: Thr-Lys-Pro-Arg-Pro-Gly-Pro (7 amino acids, tuftsin analogue)
Format: Lyophilized white powder
Storage: -20°C, desiccated
Reconstitution: Sterile bacteriostatic water

Research Context
Selank has been characterized in preclinical research primarily by Russian and Ukrainian institutions, with a growing body of international literature. In vitro applications documented in the peer-reviewed literature include GABA-A receptor interaction studies, BDNF and BDNF-TrkB signalling pathway research, serotonin and dopamine metabolism modulation studies, and enkephalin degradation inhibition assays. It is also used in comparative research on tuftsin-family immunomodulatory peptides and their neuropeptide receptor interactions.

This compound is available exclusively for in vitro laboratory research and scientific study conducted within Canada. It is not a drug, natural health product, or food product as defined under the Food and Drugs Act (R.S.C., 1985, c. F-27). It is not approved for human consumption, veterinary use, or any diagnostic or therapeutic application. This product has not been evaluated by Health Canada. Researchers are responsible for compliance with all applicable federal, provincial, and local regulations.